This site is intended to provide balanced, evidence-based, scientific information for the education of healthcare professionals licensed to practice in the United States. The information provided is not intended to provide medical advice or to promote or recommend any therapy or course of treatment. Content on the site may contain information, or links to information, about or related to investigational compounds that have not been approved by the U.S. Food and Drug Administration (FDA) and investigational, new uses of FDA-approved Bayer products. Please refer to the full Prescribing Information for approved indications, contraindications, warnings, precautions, and adverse events. If you are not a U.S. healthcare professional, please discuss any questions you have regarding your health or therapies with your healthcare provider. If you are a U.S. healthcare professional and you understand and accept the purpose and limitations of this site as described above, click “Yes” to enter the Bayer US Medical Affairs website.
Efficacy of elinzanetant for the treatment of vasomotor symptoms by duration on endocrine therapy for breast cancer: subgroup analysis of the OASIS-4 trial
This material is provided for your individual education and may not be repurposed or redistributed. It may contain information about or related to investigational new uses of FDA-approved Bayer products or investigational compounds that have not been approved by the FDA. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.
This material is provided for your individual education and may not be repurposed or redistributed. It may contain information about or related to investigational new uses of FDA-approved Bayer products or investigational compounds that have not been approved by the FDA. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.
